ESR1 and breast carcinoma: These data are consistent with previous studies for the NOS-TFs signature showing that it did not correlate with poor outcome in breast cancer [46], and with previous observations that mammaprint and proliferation signatures have only been shown to be prognostic in ER+ and HER2- breast cancer subtypes [10].